CUSHING’S SYNDROME DIAGNOSIS: TESTS, PROCEDURES, AND WHAT TO EXPECT

Cushing’s syndrome is a complex endocrine disorder resulting from prolonged exposure of the body’s tissues to high levels of cortisol. It can arise from various etiologies, broadly classified into ACTH-dependent (e.g., Cushing’s disease, ectopic ACTH production) and ACTH-independent (e.g., adrenal adenoma, iatrogenic). Accurate diagnosis, meticulous management, and proactive mitigation of complications are paramount for patient well-being.

Understanding Cushing’s Syndrome: Diagnosis, Management, and Complications

Cushing’s syndrome is a clinical condition caused by prolonged exposure to excessive cortisol. It can be endogenous (produced by the body) or exogenous (from external steroid administration). Endogenous causes are rare and include pituitary adenomas (Cushing’s disease), adrenal tumors, or ectopic ACTH-producing tumors.

1. Diagnosis of Cushing’s Syndrome

The diagnostic process for Cushing’s syndrome is multifaceted, involving initial biochemical confirmation of hypercortisolism, followed by localization of the source.

A. Clinical Suspicion: Diagnosis often begins with a high index of suspicion based on the constellation of signs and symptoms observed during history taking and physical examination (detailed later). These include central obesity, “moon” facies, “buffalo” hump, purple striae, proximal muscle weakness, hypertension, diabetes mellitus, easy bruising, and psychological disturbances.

B. Initial Biochemical Confirmation of Hypercortisolism (Screening Tests): To confirm endogenous cortisol excess, at least two distinct tests should be abnormal.

1. 24-hour Urinary Free Cortisol (UFC):
   • Principle: Measures the amount of unbound cortisol excreted in urine over 24 hours, reflecting the daily cortisol secretion.
   • Interpretation: A UFC level more than 3-4 times the upper limit of normal strongly suggests Cushing’s. Borderline elevations require retesting or additional tests.
2. Late-Night Salivary Cortisol:
   • Principle: Salivary cortisol levels reflect free, unbound cortisol. Cortisol production typically drops significantly at night. In Cushing’s, this diurnal rhythm is blunted or absent.
   • Interpretation: Elevated late-night (11 PM – Midnight) salivary cortisol on two separate occasions is indicative of hypercortisolism. It is a convenient and non-invasive test.
3. Overnight 1-mg Dexamethasone Suppression Test (LDDST):
   • Principle: Dexamethasone, a potent synthetic glucocorticoid, suppresses ACTH release from the pituitary, thereby inhibiting cortisol production in healthy individuals. In Cushing’s, this suppression is impaired.
   • Protocol: Administer 1 mg of dexamethasone orally at 11 PM – Midnight. Measure serum cortisol the following morning at 8-9 AM.
   • Interpretation: A serum cortisol level > 1.8 µg/dL (50 nmol/L) suggests Cushing’s syndrome (failure of suppression). Levels < 1.8 µg/dL generally rule out Cushing’s. Further details on DST are provided in a dedicated section.

C. Differentiating the Cause of Hypercortisolism (Localization Tests): Once hypercortisolism is confirmed, the next step is to determine the underlying etiology.

1. Plasma ACTH Measurement:
   • Principle: Differentiates ACTH-dependent from ACTH-independent Cushing’s syndrome.
   • Interpretation:
     • Low/Undetectable ACTH (< 5 pg/mL): Suggests ACTH-independent Cushing’s, most commonly an adrenal tumor producing cortisol autonomously.
     • Normal to High ACTH (≥ 15-20 pg/mL): Suggests ACTH-dependent Cushing’s, either Cushing’s disease (pituitary source) or ectopic ACTH production. Levels often > 50 pg/mL in ectopic ACTH.
     • Intermediate levels (5-15 pg/mL) can be indeterminate and require further evaluation.
2. High-Dose Dexamethasone Suppression Test (HDDST):
   • Principle: Used to differentiate pituitary-dependent Cushing’s disease from ectopic ACTH production. Pituitary adenomas are generally suppressible, though to a lesser extent than normal pituitary, while ectopic ACTH-producing tumors are typically autonomous and do not suppress.
   • Protocol: Several protocols exist, commonly the 2-day 2-mg test (2 mg dexamethasone every 6 hours for 8 doses) or the overnight 8-mg test (8 mg dexamethasone at 11 PM).
   • Interpretation:
     • Suppression: A plasma cortisol reduction of > 50% from baseline or a post-dexamethasone cortisol level below a certain threshold (e.g., < 5 µg/dL) suggests pituitary Cushing’s disease.
     • No Suppression: Lack of significant suppression suggests ectopic ACTH syndrome or, less commonly, an autonomous adrenal tumor that was missed by initial ACTH testing (though this is rare if initial ACTH was high).
   • Note: This test has limitations and may not always accurately differentiate; imaging and IPSS are often needed.
3. Corticotropin-Releasing Hormone (CRH) Stimulation Test:
   • Principle: CRH stimulates ACTH release from the pituitary. In Cushing’s disease, the pituitary is hyper-responsive to CRH, leading to an exaggerated ACTH and cortisol response. Ectopic ACTH tumors usually do not respond to CRH.
   • Interpretation: A significant rise in ACTH and cortisol after CRH administration supports Cushing’s disease.
4. Imaging Studies:
   • Pituitary MRI: Essential for identifying pituitary adenomas (Cushing’s disease).
   • Adrenal CT Scan: Used for ACTH-independent Cushing’s to locate adrenal adenomas or hyperplasia.
   • Chest CT, Abdominal/Pelvic CT, Octreotide Scan, PET Scan: Performed if ectopic ACTH production is suspected, to locate the primary tumor (e.g., small cell lung cancer, carcinoid tumors).
5. Inferior Petrosal Sinus Sampling (IPSS):
   • Principle: The gold standard for definitively differentiating Cushing’s disease from ectopic ACTH syndrome when other tests are inconclusive. It measures ACTH levels in blood samples taken directly from the veins draining the pituitary (inferior petrosal sinuses) and peripheral blood.
   • Interpretation: A central-to-peripheral ACTH gradient (>2:1 at baseline or >3:1 after CRH administration) indicates a pituitary source (Cushing’s disease). Absence of a gradient suggests an ectopic source.

2. Management of Cushing’s Syndrome

Management is highly individualized and depends on the underlying etiology. The primary goal is to normalize cortisol levels and manage associated comorbidities.

A. Cushing’s Disease (Pituitary Adenoma):

• Transsphenoidal Pituitary Adenomectomy: First-line treatment, offering high cure rates, especially for microadenomas.
• Radiation Therapy (Stereotactic Radiosurgery): Considered for residual disease or recurrence after surgery, or for patients not suitable for surgery.
• Medical Therapy: Used to control hypercortisolism when surgery fails, is contraindicated, or while awaiting the effects of radiation. Medications include:
  • Steroidogenesis Inhibitors: Ketoconazole, Metyrapone, Osilodrostat (block cortisol synthesis).
  • ACTH Release Inhibitors: Pasireotide (somatostatin analog that binds to SSTR5 on pituitary tumors).
  • Glucocorticoid Receptor Blockers: Mifepristone (for patients with type 2 diabetes or glucose intolerance who are not surgical candidates).

B. Adrenal Adenoma (ACTH-Independent):

• Unilateral Adrenalectomy: Surgical removal of the affected adrenal gland is curative. Patients will require perioperative and potentially long-term glucocorticoid replacement due to suppression of the contralateral adrenal gland.

C. Ectopic ACTH Syndrome:

• Surgical Resection of the Ectopic Tumor: If the primary tumor can be located and is resectable, this is the preferred approach.
• Bilateral Adrenalectomy: May be considered if the ectopic source cannot be found or resected, or if medical therapy fails to control severe hypercortisolism. This results in permanent adrenal insufficiency, requiring lifelong glucocorticoid and mineralocorticoid replacement.
• Medical Therapy: Steroidogenesis inhibitors (e.g., Ketoconazole, Metyrapone) are used to control hypercortisolism, especially in cases where the primary tumor is metastatic or unlocalizable.

D. Iatrogenic Cushing’s Syndrome:

• This is the most common cause, due to prolonged exogenous glucocorticoid administration. Management involves gradual tapering of the exogenous steroid dose (detailed below). Abrupt withdrawal can precipitate acute adrenal insufficiency.

3. Complications of Cushing’s Syndrome

Chronic hypercortisolism leads to a wide array of systemic complications affecting nearly every organ system.

• Metabolic: Type 2 Diabetes Mellitus, Dyslipidemia, obesity.
• Cardiovascular: Hypertension, increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), atherosclerosis.
• Musculoskeletal: Osteoporosis (leading to pathological fractures), proximal muscle weakness (myopathy), avascular necrosis.
• Dermatological: Skin thinning, easy bruising, purple striae, acne, fungal infections, hirsutism.
• Immunological: Increased susceptibility to infections, impaired wound healing.
• Psychiatric: Depression, anxiety, irritability, psychosis, cognitive impairment.
• Reproductive: Menstrual irregularities, amenorrhea, infertility in women; erectile dysfunction and decreased libido in men.
• Others: Glaucoma, cataracts, nephrolithiasis.

Successful treatment of Cushing’s syndrome usually leads to improvement or resolution of these complications, though some (e.g., severe osteoporosis, neurocognitive deficits) may persist.

The Dexamethasone Suppression Test (DST): Indications and Interpretation

The Dexamethasone Suppression Test is a cornerstone in the diagnosis and differentiation of Cushing’s syndrome. Its utility lies in assessing the integrity of the hypothalamic-pituitary-adrenal (HPA) axis feedback loop.

Indications:

• Screening for Cushing’s Syndrome: Primarily using the low-dose DST (LDDST) as a first-line diagnostic test when clinical suspicion exists.
• Differentiating Causes of Endogenous Cushing’s: High-dose DST (HDDST) helps distinguish pituitary-dependent Cushing’s disease from ectopic ACTH production.
• Evaluating Adrenal Suppression: Can be used to assess the recovery of the HPA axis after prolonged exogenous steroid use (though this is more common with ACTH stimulation tests).

Protocols and Interpretation:

1. Overnight 1-mg Low-Dose Dexamethasone Suppression Test (LDDST):
   • Protocol: Administer 1 mg of dexamethasone orally between 11:00 PM and midnight. Collect a blood sample for serum cortisol measurement the next morning between 8:00 AM and 9:00 AM.
   • Interpretation:
     • Normal (Suppression): Serum cortisol < 1.8 µg/dL (50 nmol/L). This indicates adequate suppression and generally rules out Cushing’s syndrome.
     • Abnormal (Lack of Suppression): Serum cortisol ≥ 1.8 µg/dL (50 nmol/L). This suggests hypercortisolism and warrants further investigation for Cushing’s syndrome.
   • Caveats: False positives can occur in stress, depression, alcoholism, obesity, estrogen use, and certain medications (e.g., phenytoin, phenobarbital, rifampin) that accelerate dexamethasone metabolism.
2. 48-hour 2-mg Low-Dose Dexamethasone Suppression Test (LDDST):
   • Protocol: Administer 0.5 mg of dexamethasone orally every 6 hours for 8 doses (total 2 mg over 48 hours). Collect a 24-hour urine sample for UFC on the second day, or a serum cortisol sample 6 hours after the last dose.
   • Interpretation:
     • Normal: Suppression of UFC to < 20 µg/day or serum cortisol < 1.8 µg/dL.
     • Abnormal: Failure of suppression suggests Cushing’s syndrome. This test is generally more specific than the 1-mg overnight test but less convenient.
3. High-Dose Dexamethasone Suppression Test (HDDST):
   • Purpose: To differentiate pituitary-dependent Cushing’s disease from ectopic ACTH production.
   • Protocols:
     • Overnight 8-mg HDDST: Administer 8 mg of dexamethasone orally between 11:00 PM and midnight. Measure serum cortisol the next morning at 8:00 AM.
       • Interpretation: A > 50% decrease in morning cortisol (or a post-dexamethasone cortisol level < 5 µg/dL) compared to baseline suggests Cushing’s disease. Lack of suppression suggests ectopic ACTH syndrome.
     • 48-hour 8-mg HDDST (Liddle Test): Administer 2 mg of dexamethasone orally every 6 hours for 8 doses (total 8 mg over 48 hours). Collect a 24-hour urine for UFC on the second day.
       • Interpretation: A > 50% decrease in 24-hour UFC compared to baseline suggests Cushing’s disease. Lack of suppression suggests ectopic ACTH syndrome.
   • Limitations: While helpful, HDDST results can be ambiguous. Some pituitary tumors may not suppress, and some ectopic tumors may show partial suppression. Therefore, IPSS remains the gold standard for definitive differentiation in challenging cases.

Protocol for Steroid Withdrawal in a Patient with Steroid Abuse (Iatrogenic Cushing’s)

Chronic exogenous glucocorticoid use suppresses the HPA axis, leading to adrenal atrophy and reduced endogenous cortisol production. Abrupt withdrawal can trigger a life-threatening adrenal crisis (acute adrenal insufficiency). Therefore, a gradual, monitored withdrawal protocol is essential.

Principles of Withdrawal:

1. Gradual Tapering: The primary principle is slow, stepwise reduction of the steroid dose, allowing the suppressed HPA axis to gradually recover.
2. Individualization: Tapering schedules must be individualized based on the dose, duration of therapy, patient’s underlying condition, and HPA axis recovery.
3. Monitoring for Adrenal Insufficiency: Closely observe for symptoms of recurrent adrenal insufficiency during the taper.
4. Stress Dosing: Provide “stress doses” of glucocorticoids during intercurrent illness, surgery, or other physiological stressors.

General Protocol:

1. Convert to Hydrocortisone Equivalent: If the patient is on a high-potency steroid (e.g., prednisone, dexamethasone), convert to an equivalent dose of hydrocortisone. Hydrocortisone has a shorter half-life and allows for better physiological replacement and assessment of adrenal recovery. (e.g., 5 mg Prednisone ≈ 20 mg Hydrocortisone, 0.75 mg Dexamethasone ≈ 20-25 mg Hydrocortisone).
2. Initial Taper (Supraphysiologic to Physiologic Doses):
   • Rapidly reduce the steroid dose to a more physiological range (equivalent to 20-30 mg hydrocortisone daily, taken in divided doses, e.g., 2/3 in the morning, 1/3 in the afternoon). This phase can be relatively quick (over weeks), as the HPA axis is still suppressed.
   • Monitor for symptoms of Cushing’s as the dose is reduced (e.g., improved obesity, striae fading – indicating successful withdrawal of exogenous effect) but also watch for withdrawal symptoms (fatigue, myalgia, arthralgia).
3. Slow Taper (Physiologic to Zero): This is the most critical and often longest phase.
   • Reduce the hydrocortisone dose by 2.5-5 mg every 1-2 weeks or even monthly, depending on patient tolerance and HPA axis recovery.
   • A typical tapering schedule might involve reducing to 15 mg, then 10 mg, then 5 mg or even 2.5 mg daily.
   • Monitor Symptoms: Vigilantly assess for symptoms of adrenal insufficiency (fatigue, nausea, vomiting, dizziness, weakness, myalgia, orthostatic hypotension). If symptoms occur, hold the current dose or temporarily increase it before resuming the taper.
   • Morning Cortisol Testing: After reaching a low dose (e.g., 5-10 mg hydrocortisone), measure morning (8 AM) serum cortisol levels.
     • If morning cortisol is > 10 µg/dL (275 nmol/L), consider discontinuing steroids, but monitor closely.
     • If morning cortisol is < 5 µg/dL (138 nmol/L), the HPA axis is still suppressed, and further tapering should be done very slowly or paused.
     • An ACTH stimulation test can be performed (after discontinuing steroids for 24-48 hours) to definitively assess adrenal reserve (peak cortisol > 18-20 µg/dL usually indicates adequate recovery).
4. Discontinuation and Follow-up:
   • Once the morning cortisol is consistently in the normal range (or ACTH stimulation test is normal), steroids can be safely discontinued.
   • Patient Education: Crucial. Patients must understand the risk of adrenal insufficiency and the need for stress dosing for up to 6-12 months (or even longer) after discontinuing therapy, as HPA axis recovery can be prolonged. Provide clear instructions and an emergency steroid card.
   • Follow-up: Regular follow-up appointments are necessary to monitor for adrenal insufficiency and ensure full HPA axis recovery.

The duration of withdrawal varies widely, from a few weeks to over a year, depending on the initial dose, duration of use, and individual patient factors.

History Taking for a Patient with Suspected Cushing’s Syndrome

A thorough history is crucial for identifying the characteristic symptoms and potential etiologies of Cushing’s syndrome.

1. Chief Complaint (CC):
   • Often vague and non-specific: “Weight gain,” “fatigue,” “weakness,” “changes in appearance,” “mood swings,” “menstrual problems.”
2. History of Present Illness (HPI):
   • Onset and Progression: When did symptoms begin? How have they progressed? (Often insidious and gradual).
   • Weight Gain: Describe pattern (central vs. generalized), fat redistribution (face, neck, supraclavicular, trunk).
   • Skin Changes: Easy bruising (severity, frequency), skin thinning, poor wound healing, new onset or worsening acne, hair growth (hirsutism in women: location, texture), purple/red striae (location, width), fungal infections.
   • Musculoskeletal: Proximal muscle weakness (difficulty standing from a chair, climbing stairs, lifting arms), muscle wasting, bone pain, history of fractures (especially vertebral compression fractures).
   • Cardiovascular: Hypertension (onset, severity, control), edema.
   • Metabolic: Polydipsia, polyuria (suggesting new-onset or worsening diabetes mellitus).
   • Psychological/Neurocognitive: Mood changes (depression, anxiety, irritability, lability, psychosis), insomnia, cognitive difficulties (memory, concentration).
   • Reproductive:
     • Women: Menstrual irregularities (oligomenorrhea, amenorrhea), decreased libido, infertility.
     • Men: Decreased libido, erectile dysfunction.
   • Infections: Increased frequency or severity of infections.
   • Other: Headaches, visual changes (if pituitary tumor is large), abdominal pain (if adrenal tumor or ectopic source).
3. Past Medical History (PMH):
   • Hypertension, Diabetes Mellitus, Osteoporosis, Recurrent infections, Psychiatric disorders (depression, anxiety), History of kidney stones.
   • Any previous surgeries, especially pituitary or adrenal.
4. Medication History:
   • Crucial: Ask specifically about all current and past medication use, especially corticosteroids (oral, inhaled, topical, injectable, intra-articular). Ascertain dose, duration, and reason for use. This helps differentiate iatrogenic from endogenous Cushing’s.
   • Other medications that might interfere with cortisol metabolism or DST interpretation.
5. Family History:
   • History of endocrine disorders (e.g., MEN syndromes), pituitary tumors, adrenal tumors, other autoimmune conditions.
6. Social History:
   • Occupation (stress levels), smoking, alcohol use (can cause pseudo-Cushing’s), illicit drug use.
   • Impact of symptoms on daily life, work, social interactions.
7. Review of Systems (ROS):
   • A comprehensive ROS ensures no symptom is missed, covering all major systems affected by cortisol excess.

Physical Examination of a Patient with Suspected Cushing’s Syndrome

A systematic physical examination can reveal hallmark signs that point towards Cushing’s syndrome and help assess the severity of the condition.

1. General Appearance:
   • Patient may appear plethoric (red-faced), “puffy,” centrally obese.
   • Mood: Anxious, depressed, irritable.
2. Anthropometry:
   • Weight, Height, BMI: To assess obesity.
   • Waist Circumference: Indicator of central adiposity. A high waist-to-hip ratio is characteristic.
3. Vital Signs:
   • Blood Pressure: Often elevated (hypertension). Measure in both arms, sitting and standing, for orthostatic changes.
   • Heart Rate: May be normal or slightly elevated.
4. Skin:
   • Thin, Atrophic Skin: Appears translucent, shiny.
   • Easy Bruising: Ecchymoses, often large and spontaneous.
   • Purple/Red Striae: Wide (>1 cm), purplish, located primarily on the abdomen, thighs, breasts, and arms. Distinguish from stretch marks (which are often narrower and pearly white/pink).
   • Acne: New onset or worsening.
   • Hirsutism: Excessive terminal hair growth in women, on the face, chest, abdomen, back. Assess according to Ferriman-Gallwey score.
   • Fungal/Bacterial Infections: Tinea versicolor, poor wound healing, leg ulcers.
   • Facial Plethora: Reddish, rounded facial appearance.
5. Head & Neck:
   • Moon Facies: Rounded, plethoric face with increased fat deposition.
   • “Buffalo Hump”: Dorsocervical fat pad accumulation.
   • Supraclavicular Fat Pads: Fat accumulation above the clavicles.
   • Thyroid: Palpate for goiter (less common).
6. Eyes:
   • Visual field defects (if large pituitary adenoma compressing optic chiasm).
   • Evidence of glaucoma or cataracts.
7. Chest:
   • Breast swelling/gynecomastia in males (rare, but may occur with high ACTH leading to adrenal androgen production, or direct pituitary tumor effects).
8. Abdomen:
   • Central Obesity: Prominent abdomen with relatively thin extremities.
   • Palpate for masses (rarely, large adrenal tumors may be palpable).
9. Musculoskeletal System:
   • Proximal Muscle Weakness: Test by asking the patient to stand from a squatting position without using their hands, or by assessing strength in hip flexors/extensors and shoulder abductors (e.g., inability to raise arms above head).
   • Muscle Wasting: Especially in extremities.
   • Kyphosis: May indicate vertebral compression fractures from osteoporosis.
   • Bone Pain: Tenderness on palpation of spine or long bones.
10. Neurological Examination:
    • Assess gait, reflexes, and sensation (usually normal unless there are severe electrolyte imbalances or direct tumor effects).
11. Psychiatric Evaluation:
    • Observe for signs of depression, anxiety, agitation, emotional lability, or impaired cognitive function.
12. Genitourinary System:
    • Males: Testicular atrophy, small penis size.
    • Females: Clitoromegaly (due to adrenal androgen excess, less common with primary Cushing’s disease).

The physical examination findings, coupled with a comprehensive history, guide the subsequent biochemical workup for diagnosing and localizing Cushing’s syndrome.